Follow us on Twitter
This page is updated frequently with new Cathepsin-related patents. Subscribe to the Cathepsin RSS feed to automatically get the update: related Cathepsin RSS feeds.
Subscribe to updates on this page: Cathepsin RSS
|| List of recent Cathepsin-related patents
|Cathepsin cysteine protease inhibitors|
This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.. .
|Cathepsin c inhibitors|
Disclosed are 4-amino-2-butenamides of formula (i) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin c enzyme such as chronic obstructive pulmonary disease.. .
|Aminostatin derivatives for the treatment of arthrosis|
The present invention relates to compounds of the formula (i) and in particular medicaments comprising at least one compound of the formula (i) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.. .
|Compositions and methods for inhibition of cathepsins|
This invention is directed to compound of formula i and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin k or cathepsin l, will be therapeutically useful.. .
|Method of determining the protease cathepsin b in a biological sample|
A method for determination of the potentially available activity of cathepsin b in a biological sample, including the activity of the active form of cathepsin b, the form of cathepsin b which can be activated from the pro-form procathepsin b being present in the sample, and the form of cathepsin b which can be activated and which is inhibited in the sample in its activity by protease inhibitor, whereby the procathepsin b being present in the sample is converted into the active form of cathepsin b, the free protease inhibitor for cathepsin b being present in the sample is depleted from the sample or its inhibitor function is suppressed, and the protease inhibitor is withdrawn from the inhibited form of cathepsin b, and subsequently the activity of the active cathepsin b in the sample is determined.. .
|Method for preparing virus-like particle and recombinant baculovirus used therein|
A recombinant baculovirus is provided for preparing picornavirus virus-like particles (vlp), wherein chitinase a (chia) and cathepsin v (v-cath) genes of the recombinant baculovirus are functionally disrupted and the recombinant baculovirus includes a picornavirus capsid protein gene under control of a strong promoter, and includes a protease gene configured for encoding a protease for hydrolyzing the capsid protein under control of a weak promoter. The recombinant baculovirus of the present invention may adopt high five or sf-9 cells for manufacturing enterovirus virus-like particles with improved stability and higher yields in comparison with the conventional arts.
|Protease degradable polypeptides and uses thereof|
Provided herein are polypeptides that are selectively cleaved by cathepsin e. Also provided are methods of detecting cathepsin e.
Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .
|Formulations for cathepsin k inhibitors|
The instant invention relates to pharmaceutical compositions containing cathespin k inhibitors. Also disclosed are processes for making said pharmaceutical compositions..
|Method of identifying triple negative breast cancer|
The present invention provides means for identifying or classifying breast tumors based on the levels of nuclear cathepsin-l (ctsl) and nuclear p53 binding protein (53bp1), and methods of treating thereof.. .
|Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c|
And their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.. .
|Cysteine protease inhibitors|
For the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin s.. .
|Methods and compositions for diagnosis and prognosis of renal injury and renal failure|
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of cancer antigen ca 15-3, c-c motif chemokine 18, c-c motif chemokine 24, cathepsin d, c-x-c motif chemokine 13, c-c motif chemokine 8, interleukin-2 receptor alpha chain, insulin-like growth factor-binding protein 3, interleukin-11, matrix metalloproteinase-8, transforming growth factor alpha, igg1, and igg2 as diagnostic and prognostic biomarkers in renal injuries..
|Heteroaryl nitrile compounds useful as inhibitors of cathepsin-s|
Disclosed are cathepsin-s reversible inhibitor compounds of the formula (i) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same..
|Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors|
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
|Process for the preparation of proline derivatives|
The proline derivatives of the formula i are preferential inhibitors of the cysteine protease cathepsin s and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease and diabetic nephropathy.. .
|Inhibition of cathepsin k activity and the treatment and prevention of disease|
The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates cathepsin k activity.. .
|3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals|
Wherein ht, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
|Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals|
Wherein g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
|Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals|
The present invention relates to compounds of the formula i, wherein a, d, e, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
|Cathepsin cysteine protease inhibiors|
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis..
Popular terms: [SEARCH]
Cathepsin topics: Protease Inhibitor, Protease Inhibitors, Atherosclerosis, Recombinant, Osteoarthritis, Rheumatoid Arthritis, Steoporosis, Osteoporosis, Polypeptide, Nanoparticle, Fluorescence, Inflammatory Disease, Liver Diseases, Enterovirus, Virus Like Particle
Follow us on Twitter
This listing is a sample listing of patents related to Cathepsin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cathepsin with additional patents listed. Browse our RSS directory or Search for other possible listings.